Sesen Bio, Inc. (SESN): Price and Financial Metrics

Sesen Bio, Inc. (SESN): $0.58

-0.01 (-1.64%)

POWR Rating

Component Grades













Add SESN to Watchlist
Sign Up

Industry: Biotech



in industry


  • SESN scores best on the Value dimension, with a Value rank ahead of 98.89% of US stocks.
  • The strongest trend for SESN is in Growth, which has been heading up over the past 177 days.
  • SESN's current lowest rank is in the Momentum metric (where it is better than 5.23% of US stocks).

SESN Stock Summary

  • Of note is the ratio of SESEN BIO INC's sales and general administrative expense to its total operating expenses; merely 15.69% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for SESEN BIO INC is higher than it is for about just 0.48% of US stocks.
  • As for revenue growth, note that SESN's revenue has grown 816.87% over the past 12 months; that beats the revenue growth of 98.61% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to SESEN BIO INC, a group of peers worth examining would be IPA, VMAR, INM, SNCR, and ABEO.
  • Visit SESN's SEC page to see the company's official filings. To visit the company's web site, go to

SESN Valuation Summary

  • In comparison to the median Healthcare stock, SESN's price/sales ratio is 0% higher, now standing at 2.1.
  • Over the past 109 months, SESN's price/sales ratio has gone down 117.4.

Below are key valuation metrics over time for SESN.

Stock Date P/S P/B P/E EV/EBIT
SESN 2023-01-30 2.1 0.7 -36.6 -7.2
SESN 2023-01-27 2.1 0.8 -37.8 -7.8
SESN 2023-01-26 2.1 0.8 -36.8 -7.4
SESN 2023-01-25 2.1 0.8 -37.8 -7.8
SESN 2023-01-24 2.1 0.8 -37.7 -7.7
SESN 2023-01-23 2.1 0.8 -37.7 -7.8

SESN Growth Metrics

    Its 5 year revenue growth rate is now at -100%.
  • Its 5 year net cashflow from operations growth rate is now at -741.91%.
  • The year over year price growth rate now stands at -80.5%.
SESN's revenue has moved up $60,000,000 over the prior 30 months.

The table below shows SESN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 60 9.614 -3.381
2022-06-30 20 -28.703 47.799
2022-06-30 20 -28.703 47.799
2022-03-31 22.234 -43.249 54.317
2021-12-31 26.544 -68.878 -0.336
2021-09-30 6.544 -64.787 -24.341

SESN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SESN has a Quality Grade of C, ranking ahead of 52.29% of graded US stocks.
  • SESN's asset turnover comes in at 0.094 -- ranking 266th of 682 Pharmaceutical Products stocks.
  • SVRA, AUPH, and ONVO are the stocks whose asset turnover ratios are most correlated with SESN.

The table below shows SESN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.094 1 511.326
2021-03-31 0.120 1 31.068
2020-12-31 0.103 1 4.319
2020-09-30 0.105 1 14.394
2020-06-30 0.000 NA 7.880
2020-03-31 0.000 NA 13.068

SESN Price Target

For more insight on analysts targets of SESN, see our SESN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.25 Average Broker Recommendation 1.67 (Moderate Buy)

SESN Stock Price Chart Interactive Chart >

Price chart for SESN

SESN Price/Volume Stats

Current price $0.58 52-week high $0.97
Prev. close $0.59 52-week low $0.37
Day low $0.57 Volume 821,600
Day high $0.59 Avg. volume 801,638
50-day MA $0.57 Dividend yield N/A
200-day MA $0.60 Market Cap 117.70M

Sesen Bio, Inc. (SESN) Company Bio

Sesen Bio (formerly Eleven Biotherapeutics, Inc.), a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts.

SESN Latest News Stream

Event/Time News Detail
Loading, please wait...

SESN Latest Social Stream

Loading social stream, please wait...

View Full SESN Social Stream

Latest SESN News From Around the Web

Below are the latest news stories about SESEN BIO INC that investors may wish to consider to help them evaluate SESN as an investment opportunity.

Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger

CAMBRIDGE, Mass., February 02, 2023--Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. ("Carisma"). The presentation can be found at

Yahoo | February 2, 2023

The Petri Dish: Departed White House adviser returns to the Broad

The founding director of the Broad Institute of MIT and Harvard is set to return to the research organization a year after leaving a top post at the White House.

Yahoo | February 2, 2023

Sesen Bio Receives NASDAQ Delisting Notice

CAMBRIDGE, Mass., January 30, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company") today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company’s common stock is subject to delisting.

Yahoo | January 30, 2023

Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders

CAMBRIDGE, Mass., January 26, 2023--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the "Investor Group"):

Yahoo | January 26, 2023

Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support

HOUSTON, January 25, 2023--Bradley L. Radoff and Michael Torok (together with their affiliates, the "Investor Group" or "we"), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio"), today issued the following open letter to the Boards of Directors (collectively, the "Boards") of Sesen Bio and Carisma Therapeutics Inc. ("Carisma" and together with Sesen Bio, the "Companies"):

Yahoo | January 25, 2023

Read More 'SESN' Stories Here

SESN Price Returns

1-mo -8.17%
3-mo 6.48%
6-mo -17.61%
1-year -21.23%
3-year -38.07%
5-year -30.79%
YTD -4.84%
2022 -25.21%
2021 -39.63%
2020 29.81%
2019 -26.76%
2018 75.09%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7052 seconds.